Second study participant dies during Eisai’s Alzheimer’s drug trial

A second study participant has died possibly as a result of the experimental antibody drug, lecanemab, meant to treat Alzheimer's, Science reported Nov. 27.

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive